Abstract: Objective To investigate the clinical efficacy，tolerability and safety of  three-dimensional conformal radiation therapy （3DCRT）/intensity-modulated radiation therapy（IMRT）and synchronous cisplatin chemotherapy combined with nimotuzumab for previously untreated，locally advanced nasopharyngeal carcinoma. Methods 40 patients with untreated，locally advanced nasopha-ryngeal carcinoma were enrolled.All patients received 3DCRT/IMRT and synchronous cisplatin chemotherapy combined with nimo-tuzumab.Planned IMRT doses in the target region were 69.96-73.92 Gy for PGTVnx，69.96-73.92 Gy for PGTVnd，60-66 Gy for PTV-1 and 54-56 Gy for PTV-2 in 33 fractions.Cisplatin（80 mg/m² on the first day of each cycle，once every 3 weeks for a total of  2 cycles）was given concurrently with Nimotuzumab（100 mg on day 1 of radiotherapy，then once a week for a total of 8 times）. Clinical efficacy，tolerability and safety were analyzed during follow-up. Results All 40 patients completed the treatment as planned，and all patients were followed up at least 24 months. Only one patient suffered local recurrence during follow-up.At 6 months after treatment，response rate（RR） in terms of both primary lesions and positive lymph nodes was 97.5%. Acute side effects during treatment included 9 cases of grade 3 bone marrow suppression and 8 cases of grade 3 oral mucositis.No grade 4 toxicity occurred. Conclusion 3DCRT/IMRT and synchronous cisplatin chemotherapy combined with nimotuzumab showed good clinical efficacy，tolerability and safety，suggesting that the teatment can be recommended.

Key words: Nasopharyngeal neoplasm, 3DCRT/IMRT, Concurrent chemotherapy, Molecular targeted therapy, Nimotuzumab